Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and their pancreatic cancer. This study will involve two different treatment arms. In Arm A, patients will receive niraparib plus ipilimumab. In Arm B, patients will receive standard chemotherapy. The main questions the study aims to answer are: * Does niraparib plus ipilimumab slow down tumor growth in patients with pancreatic cancer? * What medical problems do participants have when taking niraparib plus ipilimumab? Participants will: * Undergo screening procedures to evaluate their cancer, overall health, and suitability for the study * After passing screening, will be randomized to Arm A or B and be scheduled to receive niraparib plus ipilimumab (Arm A) or chemotherapy (Arm B) * Receive niraparib plus ipilimumab every 3 weeks (Arm A) * Receive chemotherapy every 2 weeks (Arm B) * Visit the clinic for regular checkups and tests
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak trzustki z przerzutami, potwierdzony badaniem histologicznym lub cytologicznym.
- •Pacjent ma co najmniej 18 lat.
- •Pacjent rozumie zasady badania i zgadza się na udział, podpisując formularz świadomej zgody.
- •Pacjent otrzymał wcześniej 8-12 cykli (4-6 miesięcy) pierwszego leczenia FOLFIRINOX lub zmodyfikowanego FOLFIRINOX, a choroba pozostała stabilna lub uległa poprawie.
- •Pacjent jest gotów poddać się pobraniu próbki guza przed leczeniem (jeśli to możliwe).
- •Pacjent jest gotów poddać się pobraniu próbki guza w trakcie leczenia (jeśli to możliwe).
- •Kobiety w wieku rozrodczym muszą mieć negatywny test ciążowy i zgadzają się na stosowanie antykoncepcji.
- •Mężczyźni zgadzają się na stosowanie antykoncepcji.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Dana-Farber Cancer Institute
Boston, United States
University of Pennsylvania, Abramson Cancer Center
Philadelphia, United States
Trial contact
Kim Reiss Binder, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.